CELON PHARMA S.A. ZY-10

Research CELON PHARMA S.A. ZY-10 (8RP) on Bullrun: market cap EUR 192.42M, P/E 10.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 192.42M; P/E is 10.5.

Peer valuation comparison

Latest P/E is 10.52x versus a Healthcare sector median of 24.46x (57.0% below).

Latest P/E is 10.52x versus a Poland median of 13.21x (20.3% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025n/a-PLN 79.08MPLN 23.85Mn/an/aPLN 1.27MPLN 14.19MPLN 363.25M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27EUR 192.42M10.5n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About CELON PHARMA S.A. ZY-10

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is CELON PHARMA S.A. ZY-10's market cap?

CELON PHARMA S.A. ZY-10's market capitalization is EUR 192.42M.

What is CELON PHARMA S.A. ZY-10's P/E ratio?

CELON PHARMA S.A. ZY-10's price-to-earnings (P/E) ratio is 10.5.

What does CELON PHARMA S.A. ZY-10 do?

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.